Traductor

27 September 2010

Sanofi-aventis approaches lenders about raising Genzyme offer - report

According to people familiar with the situation, sanofi-aventis is contemplating raising its takeover bid for Genzyme, The Wall Street Journal reported. The French drugmaker has previously been hesitant to raise its offer for Genzyme, but is said to be considering the move in order to spur takeover discussions.
Sanofi-aventis spokesman Jean-Marc Podvin noted that the company "would like to enter into a dialogue" with Genzyme, but he declined to comment on the report of an increased offer price. "We have one offer at $69. No other offer has been made," Podvin said.
The sources note that the French drugmaker recently asked Genzyme to declare a price at which due diligence can begin, but Genzyme has so far declined, saying that it would not benefit by disclosing a figure. Sanofi-aventis has said that its preference is to keep takeover discussions friendly, but people familiar with the situation have previously reported that the company has not ruled out a hostile takeover.
Last month, Genzyme CEO Henri Termeer said that if the company did enter into negotiations with sanofi-aventis, it would likely open up the sales process to others, the Wall Street Journal reports. To date, no other interested parties have submitted a takeover bid.

Reference Articles
Sanofi may raise Genzyme bid, looking for financing, WSJ says - (Bloomberg)
Sanofi lining up Genzyme financing (free preview) - (The Wall Street Journal)
Sanofi says holds offer for Genzyme at $69/shr - (Yahoo!Finance)

**Published in "First Word"

No comments:

Post a Comment

CONTACTO · Aviso Legal · Política de Privacidad · Política de Cookies

Copyright © Noticia de Salud